Anti Inflammatory News and Research

RSS

Study Connects Gut Bacteria Patterns With Dyslipidemia Risk

Before the onset of cardiovascular disease symptoms, people often develop dyslipidemia, or abnormal levels of lipids in the blood.

5 Mar 2026

Scientists Develop Novel Tool to Profile Elusive HIV Reservoir Cells

For people living with human immunodeficiency virus (HIV), life-saving antiretroviral therapy keeps their HIV-infected immune cells from making new copies of the virus, preventing illness and transmission.

4 Mar 2026

Engineered E. coli Produces Key Plant Compound at Record Levels

Researchers engineered E. coli to produce orsellinic acid-derived meroterpenoids, offering a sustainable alternative to traditional plant extraction methods.

25 Feb 2026

Microbial Engineering Breakthrough Improves Supply of Promising Pharmaceuticals

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

18 Feb 2026

Understanding Inter-Micellar Interactions Governing Drug Nanocarriers

Polymer micelles are tiny, self-assembled particles that are revolutionizing the landscape of drug delivery and nanomedicine.

10 Feb 2026

Novel Hydrogel Stops Infection and Speeds Wound Recovery

A novel gel might help combat resistant bacteria in wounds and around implant sites while also promoting recovery. The hydrogel, which is inspired by natural immune defenses, has generated extremely encouraging outcomes in animal models.

4 Feb 2026

Gut Microbial Metabolite Hippuric Acid Amplifies Immune Responses

Scientists at The Wistar Institute have identified a previously overlooked mediator in the body's response to life-threatening infections: hippuric acid, a metabolite produced when gut bacteria break down polyphenols from berries, tea, and other plant-based foods.

31 Jan 2026

Yeast-Based Platform Achieves Animal-Free High Quality Chondroitin Sulfate

By systematically redesigning multiple metabolic modules inside Komagataella phaffii, the researchers achieved both high product yield and high sulfation quality, two goals that have long been difficult to reach at the same time.

21 Jan 2026

Foreign RsMYB28 Allele Boosts Glucosinolate Accumulation in Rapeseed

These bioactive compounds, found primarily in Brassicaceae plants, play crucial roles in plant defense, contribute to distinctive food flavors, and have potential health benefits, including cancer prevention.

23 Dec 2025

Kefir-Derived Bacteria Show Potential to Reverse Age-Related Immune Decline

The process of aging is associated with a decline in immune functions and persistent low-level inflammation.

18 Dec 2025

Smart Hydrogel Senses Infected Wounds and Delivers the Right Treatment

The novel hydrogel adapts to wound environments, offering precise antibacterial and regenerative support, addressing the challenges of infected wounds.

18 Dec 2025

How Tumor Stem Cells Hijack Neutrophils to Evade Immunotherapy

Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors.

9 Dec 2025

Breakthrough Reveals How Immune Cells Orchestrate Pathological Scarring

Researchers at the University of Arizona uncovered a previously unknown population of circulating immune cells that play a critical role in fibrosis, the buildup of scar tissue that can lead to organ failure and disfigurement.

26 Nov 2025

Discovery of Glucocorticoid Receptor Multimerization Opens Path to Safer Therapies

Drugs to treat inflammatory and autoimmune diseases - such as asthma, psoriasis, rheumatoid arthritis or Chrousos syndrome - act mainly through the glucocorticoid receptor (GR).

28 Oct 2025

RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics

RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond.

From Lonza 26 Sep 2025